GlassScriptPhysician profile
Craig A Skolnick
NPI 1689699654
$5,511.51
in general payments reported to CMS, 2019-2025
28 companies · $707 in 2025
The $707 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $597 · 2021: $1,035 · 2022: $935 · 2023: $560 · 2024: $669 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,935.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $623.29 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $589.57 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $570.08 | 2021-2024 | Acthar |
| Bausch & Lomb Americas INC. | $475.95 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Alcon Vision LLC | $472.61 | 2019-2025 | Rocklatan, Simbrinza, Rhopressa |
| Sun Pharmaceutical Industries INC. | $391.36 | 2019-2025 | Cequa |
| Allergan, INC. | $381.08 | 2019-2022 | |
| Dompe US, INC. | $222.10 | 2019-2025 | Oxervate |
| Abbvie INC. | $210.66 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Aerie Pharmaceuticals, INC. | $182.72 | 2019-2021 | |
| Harrow Eye, LLC | $172.02 | 2025 | Vevye |
| Beaver-Visitec International, INC. | $145.73 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $142.05 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $140.07 | 2019-2023 | Flarex |
| Oyster Point Pharma, INC. | $118.08 | 2022-2025 | Tyrvaya, Ryzumvi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $117.31 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $101.01 | 2019-2023 | Tecnis Iol |
| Astellas Pharma US INC | $78.93 | 2024-2025 | Izervay |
| Biotissue Holdings INC. | $64.61 | 2019-2022 | |
| Shire North American Group INC | $63.41 | 2019 | |
| Kala Pharmaceuticals, INC. | $63.06 | 2019-2021 | |
| Amgen INC. | $42.94 | 2025 | Tepezza |
| Thea Pharma INC. | $41.66 | 2024 | Iyuzeh |
| Alcon Research LLC | $24.97 | 2019 | |
| Ani Pharmaceuticals, INC. | $24.35 | 2024 | Purified Cortrophin Gel |
| Sight Sciences, INC. | $20.33 | 2019 | |
| Smith+Nephew, INC. | $16.76 | 2020 | |
| Tearlab Corp | $14.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Skolnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.